Eyegate Pharma Cmn (EYEG) 1.56 $EYEG
EyeGate Pharmaceuticals to Present at the 2016 Aegis Capital Conference
GlobeNewswire - Wed Sep 21, 7:30AM CDT
EyeGate Pharmaceuticals, Inc. (Nasdaq:EYEG), ("EyeGate" or the "Company"
, a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that Stephen From, President & Chief Executive Officer of EyeGate, is scheduled to present at the 2016 Aegis Capital Corp. Investment Growth Conference, being held September 21 and 22, 2016 at the Encore at Wynn Las Vegas in Las Vegas, NV.
EYEG: 1.56 (-0.05)
EyeGate Awarded $448,185 for second year of funding of Phase II SBIR Grant from U.S. Department of Defense
GlobeNewswire - Tue Sep 13, 7:30AM CDT
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company" , a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that Jade Therapeutics, Inc. ("Jade" , a wholly owned subsidiary of EyeGate, has received the second year of funding of $448,185 from the U.S. Army Medical Research and Materiel Command (USAMRMC) to continue the development of its proprietary thiolated hyaluronic acid (CMHA-S) for use as an ocular bandage film entitled "Novel Hyaluronic Acid Delivery Polymer for Repair of Ocular Injuries". The second year of funding brings the total awarded to Jade under the U.S. Army's Small Business Innovation Research (SBIR) program to $1.25 million. This work is supported by the U.S. Army Medical Research and Materiel Command under Contract No. W81XWH-14-C-0025.
EYEG: 1.56 (-0.05)
EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437
GlobeNewswire - Mon Sep 12, 7:30AM CDT
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company" , a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that it has received an additional development milestone from a subsidiary of Valeant Pharmaceuticals International, Inc. ("Valeant" under the Company's License Agreement with Valeant, pursuant to which EyeGate has granted Valeant exclusive, worldwide commercial and manufacturing rights to the Company's EyeGate(R) II Delivery System and EGP-437 combination product (the "Product" in the field of uveitis, as well as a right of last negotiation to license the Product for other indications.
EYEG: 1.56 (-0.05), VRX.TO: 35.07 (-0.27)
EyeGate Pharmaceuticals to Present at the 18th Annual Rodman and Renshaw Global Investment Conference
GlobeNewswire - Tue Sep 06, 7:30AM CDT
EYEG (Nasdaq:EYEG), ("EyeGate" or the "Company" , a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that Stephen From, President & Chief Executive Officer of EyeGate, is scheduled to present at the 18 Annual Rodman & Renshaw Global Investment Conference being held September 11-13, 2016 at the Lotte New York Palace Hotel in New York, NY.
EYEG: 1.56 (-0.05)
EyeGate Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
GlobeNewswire - Wed Aug 10, 3:49PM CDT
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company" , a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced financial results for the three-month period ended June 30, 2016, and provided an update on recent corporate and operational activities.
EYEG: 1.56 (-0.05)
EyeGate Announces Positive Top-line Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Post-Operative Inflammation and Pain in Cataract Surgery Patients
GlobeNewswire - Mon Aug 01, 7:30AM CDT
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company" , a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced positive data from its Phase 1b/2a trial assessing its lead product candidate, iontophoretic EGP-437, in the treatment of post-operative ocular inflammation and pain in cataract surgery patients.
EYEG: 1.56 (-0.05)
EyeGate Announces Encouraging Interim Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Ocular Inflammation and Pain Post Cataract Surgery
GlobeNewswire - Wed Jun 01, 7:30AM CDT
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company" , a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced interim data from its Phase 1b/2a trial evaluating its lead product candidate, iontophoretic EGP-437, in the treatment of ocular inflammation and pain in cataract surgery patients.
EYEG: 1.56 (-0.05)
EyeGate Pharma Announces At The Market Issuance Program
GlobeNewswire - Tue May 24, 5:00PM CDT
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (the "Company" announced today that it has entered into an At The Market Issuance ("ATM" Sales Agreement, dated May 24, 2016, with H.C. Wainwright & Co., LLC (the "Sales Agent" , under which the Company may, at its discretion and from time to time during the term of the ATM Sales Agreement, sell up to a maximum of 1,319,289 shares of its common stock through ATM issuances on the NASDAQ Capital Market. The Sales Agent will act as sales agent for any sales made under this new ATM program. The shares of common stock will be sold at market prices prevailing at the time of the sale of such shares and, as a result, sale prices may vary.
EYEG: 1.56 (-0.05)
Eyegate Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update
GlobeNewswire - Fri May 13, 4:24PM CDT
Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company" , a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced financial results for the three-month period ended March 31, 2016 and provided an update on recent corporate and operational initiatives.
EYEG: 1.56 (-0.05)
EyeGate Pharma Appoints Dr. Brenda K. Mann as Vice President, Research and Development
GlobeNewswire - Fri May 06, 7:30AM CDT
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company" , a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that, following the Company's recent acquisition of Jade Therapeutics, former Jade Vice President of Research and Development, Dr. Brenda K. Mann, was named Vice President, Research and Development at EyeGate. Dr. Mann is responsible for overseeing the Company's scientific development strategy, managing portfolio assets including early stage programs and building the company's scientific direction.
EYEG: 1.56 (-0.05)
EyeGate Pharma Appoints Ryan R. Brenneman as Chief Financial Officer
GlobeNewswire - Wed Apr 27, 3:05PM CDT
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company" , a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced the appointment of Ryan R. Brenneman, CPA, JD, as its Chief Financial Officer, effective April 25, 2016. Mr. Brenneman will lead the Company's financial and administrative operations.
EYEG: 1.56 (-0.05)
EyeGate Pharma to Present Four Posters at ARVO 2016 Annual Meeting Supporting Development of CMHA-S
GlobeNewswire - Tue Apr 26, 7:30AM CDT
Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company" , a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that four abstracts supporting the ongoing development of its proprietary technology cross-linked hyaluronic acid polymer (CMHA-S) have been accepted for poster presentation at the upcoming 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) being held May 1-5, 2016 in Seattle, WA.
EYEG: 1.56 (-0.05)
4 Stocks That are Making Big Moves Early Today
ACCESSWIRE - Tue Feb 02, 9:23AM CST
NEW YORK, NY / ACCESSWIRE / February 2, 2016 / The Stock Expert is issuing a report on four stocks to watch. HDP, EYEG, LOJN and HNSN have been attracting the attention of major investors today. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
HDP: 8.78 (+0.51), HNSN: 3.99 (unch), LOJN: 6.44 (-0.01), EYEG: 1.56 (-0.05)
Macular Edema - Pipeline Review 2015
M2 - Fri Jan 29, 9:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/3t295k/macular_edema) has announced the addition of the "Macular Edema - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Macular Edema and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - ActiveSite Pharmaceuticals, Inc. - Allergan Plc - Chong Kun Dang Pharmaceutical Corp. - Clearside BioMedical, Inc. - EyeGate Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - Mabion SA - Pfizer Inc. - Promedior, Inc. - Taiwan Liposome Company, Ltd. - Xbrane Bioscience AB Key Topics Covered: - Introduction - Macular Edema Overview - Therapeutics Development - Pipeline Products for Macular Edema - Overview - Pipeline Products for Macular Edema - Comparative Analysis - Macular Edema - Therapeutics under Development by Companies - Macular Edema - Therapeutics under Investigation by Universities/Institutes - Macular Edema - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Macular Edema - Products under Development by Companies - Macular Edema - Products under Investigation by Universities/Institutes - Macular Edema - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/3t...ular_edema
AGN: 243.43 (+5.02), CLSD: 11.75 (-0.13), EYEG: 1.56 (-0.05), PFE: 34.15 (-0.13)
Cataract - Pipeline Review - Companies Mentioned Include EyeGate Pharmaceuticals, InSite Vision Incorporated, Laboratories Sophia S.A. de C.V., Omeros Corporation & R-Tech Ueno
M2 - Fri Jan 29, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/bvgpjg/cataract) has announced the addition of the "Cataract - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cataracts, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cataract and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - EyeGate Pharmaceuticals, Inc. - InSite Vision Incorporated - Laboratorios Sophia S.A. de C.V. - Omeros Corporation - R-Tech Ueno, Ltd. Key Topics Covered: - Introduction - Cataract Overview - Therapeutics Development - Pipeline Products for Cataract - Overview - Pipeline Products for Cataract - Comparative Analysis - Cataract- Therapeutics under Development by Companies - Cataract- Therapeutics under Investigation by Universities/Institutes - Cataract- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cataract- Products under Development by Companies - Cataract- Products under Investigation by Universities/Institutes - Cataract- Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/bvgpjg/cataract
EYEG: 1.56 (-0.05), OMER: 11.90 (+0.39)
Retinal Vein Occlusion Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/prcfm8/retinal_vein) has announced the addition of the "Retinal Vein Occlusion - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Retinal Vein Occlusion Overview - Therapeutics Development - Pipeline Products for Retinal Vein Occlusion - Overview - Pipeline Products for Retinal Vein Occlusion - Comparative Analysis - Retinal Vein Occlusion - Therapeutics under Development by Companies - Retinal Vein Occlusion - Therapeutics under Investigation by Universities/Institutes - Retinal Vein Occlusion - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Retinal Vein Occlusion - Products under Development by Companies - Retinal Vein Occlusion - Products under Investigation by Universities/Institutes - Retinal Vein Occlusion - Companies Involved in Therapeutics Development - Aerpio Therapeutics, Inc. - Allergan Plc - Avalanche Biotechnologies, Inc. - EyeGate Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Kala Pharmaceuticals, Inc. - Mabion SA - NicOx S.A. - Ohr Pharmaceutical Inc. - pSivida Corp. - ThromboGenics NV For more information visit http://www.researchandmarkets.com/research/pr...tinal_vein
AGN: 243.43 (+5.02), EYEG: 1.56 (-0.05), OHRP: 2.78 (+0.03), AAVL: 4.14 (-0.18)
EyeGate Pharma Enrolls First Patient in Confirmatory Phase 3 Clinical Trial EGP-437-006 for Non-Infectious Anterior Uveitis
GlobeNewswire - Tue Jan 19, 7:30AM CST
Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company" , a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that the first patient was enrolled in the Company's confirmatory Phase 3 clinical trial of its EGP-437 combination product, the Company's lead product, in patients with non-infectious anterior uveitis, an inflammation of the anterior chamber of the eye.
EYEG: 1.56 (-0.05)
Eyegate Pharmaceuticals to Present at the Noble Financial Capital Markets' 12th Annual Investor Conference
GlobeNewswire - Thu Jan 14, 8:49AM CST
Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (NASDAQ:EYEGW) ("EyeGate" or the "Company" , a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced Stephen From, President & Chief Executive Officer of EyeGate, is scheduled to present at the Noble Financial Capital Markets' 12 Annual Conference, being held January 17-20, 2016 in Sandpiper Bay, Florida.
EYEG: 1.56 (-0.05), EYEGW: 0.50 (-0.17)
Diabetic Macular Edema Pipeline Review, H2 2015
M2 - Fri Dec 04, 5:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/nznc34/diabetic_macular) has announced the addition of the "Diabetic Macular Edema - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aciont Inc. - ActiveSite Pharmaceuticals, Inc. - Acucela Inc. - Aerpio Therapeutics, Inc. - Allergan Plc - Ampio Pharmaceuticals, Inc. - Astellas Pharma Inc. - Avalanche Biotechnologies, Inc. - Chengdu Kanghong Pharmaceuticals Group Co., Ltd. - Chong Kun Dang Pharmaceutical Corp. - Dyax Corp. - EyeGate Pharmaceuticals, Inc. - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Genmab A/S - Icon Bioscience, Inc. - Kala Pharmaceuticals, Inc. - Kowa Company, Ltd. - Mabion SA - MacuCLEAR, Inc. - NicOx S.A. - Oculis ehf - Ohr Pharmaceutical Inc. - Pfizer Inc. - Quark Pharmaceuticals, Inc. - R-Tech Ueno, Ltd. - Regeneron Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - SciFluor Life Sciences, LLC - Senju Pharmaceutical Co., Ltd. - ThromboGenics NV - Verseon Corporation For more information visit http://www.researchandmarkets.com/research/nz...ic_macular
PFE: 34.15 (-0.13), AMPE: 0.89 (unch), DYAX: 38.04 (-0.37), AGN: 243.43 (+5.02), EYEG: 1.56 (-0.05), AAVL: 4.14 (-0.18), OHRP: 2.78 (+0.03), REGN: 408.01 (+1.49)
EyeGate Reports Third Quarter 2015 Financial Results and Provides Business Update
GlobeNewswire - Thu Nov 12, 7:30AM CST
Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company" , a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced financial results for the three months ended September 30, 2015 and provided an update on recent strategic and operational initiatives.
VRX: 26.85 (-0.12), EYEG: 1.56 (-0.05), VRX.TO: 35.07 (-0.27)
EyeGate Pharmaceuticals to Present at the 2016 Aegis Capital Conference
GlobeNewswire - Wed Sep 21, 7:30AM CDT
EyeGate Pharmaceuticals, Inc. (Nasdaq:EYEG), ("EyeGate" or the "Company"
, a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that Stephen From, President & Chief Executive Officer of EyeGate, is scheduled to present at the 2016 Aegis Capital Corp. Investment Growth Conference, being held September 21 and 22, 2016 at the Encore at Wynn Las Vegas in Las Vegas, NV. EYEG: 1.56 (-0.05)
EyeGate Awarded $448,185 for second year of funding of Phase II SBIR Grant from U.S. Department of Defense
GlobeNewswire - Tue Sep 13, 7:30AM CDT
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company"
, a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that Jade Therapeutics, Inc. ("Jade" , a wholly owned subsidiary of EyeGate, has received the second year of funding of $448,185 from the U.S. Army Medical Research and Materiel Command (USAMRMC) to continue the development of its proprietary thiolated hyaluronic acid (CMHA-S) for use as an ocular bandage film entitled "Novel Hyaluronic Acid Delivery Polymer for Repair of Ocular Injuries". The second year of funding brings the total awarded to Jade under the U.S. Army's Small Business Innovation Research (SBIR) program to $1.25 million. This work is supported by the U.S. Army Medical Research and Materiel Command under Contract No. W81XWH-14-C-0025. EYEG: 1.56 (-0.05)
EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437
GlobeNewswire - Mon Sep 12, 7:30AM CDT
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company"
, a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that it has received an additional development milestone from a subsidiary of Valeant Pharmaceuticals International, Inc. ("Valeant" under the Company's License Agreement with Valeant, pursuant to which EyeGate has granted Valeant exclusive, worldwide commercial and manufacturing rights to the Company's EyeGate(R) II Delivery System and EGP-437 combination product (the "Product" in the field of uveitis, as well as a right of last negotiation to license the Product for other indications. EYEG: 1.56 (-0.05), VRX.TO: 35.07 (-0.27)
EyeGate Pharmaceuticals to Present at the 18th Annual Rodman and Renshaw Global Investment Conference
GlobeNewswire - Tue Sep 06, 7:30AM CDT
EYEG (Nasdaq:EYEG), ("EyeGate" or the "Company"
, a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that Stephen From, President & Chief Executive Officer of EyeGate, is scheduled to present at the 18 Annual Rodman & Renshaw Global Investment Conference being held September 11-13, 2016 at the Lotte New York Palace Hotel in New York, NY. EYEG: 1.56 (-0.05)
EyeGate Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
GlobeNewswire - Wed Aug 10, 3:49PM CDT
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company"
, a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced financial results for the three-month period ended June 30, 2016, and provided an update on recent corporate and operational activities. EYEG: 1.56 (-0.05)
EyeGate Announces Positive Top-line Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Post-Operative Inflammation and Pain in Cataract Surgery Patients
GlobeNewswire - Mon Aug 01, 7:30AM CDT
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company"
, a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced positive data from its Phase 1b/2a trial assessing its lead product candidate, iontophoretic EGP-437, in the treatment of post-operative ocular inflammation and pain in cataract surgery patients. EYEG: 1.56 (-0.05)
EyeGate Announces Encouraging Interim Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Ocular Inflammation and Pain Post Cataract Surgery
GlobeNewswire - Wed Jun 01, 7:30AM CDT
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company"
, a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced interim data from its Phase 1b/2a trial evaluating its lead product candidate, iontophoretic EGP-437, in the treatment of ocular inflammation and pain in cataract surgery patients. EYEG: 1.56 (-0.05)
EyeGate Pharma Announces At The Market Issuance Program
GlobeNewswire - Tue May 24, 5:00PM CDT
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (the "Company"
announced today that it has entered into an At The Market Issuance ("ATM" Sales Agreement, dated May 24, 2016, with H.C. Wainwright & Co., LLC (the "Sales Agent" , under which the Company may, at its discretion and from time to time during the term of the ATM Sales Agreement, sell up to a maximum of 1,319,289 shares of its common stock through ATM issuances on the NASDAQ Capital Market. The Sales Agent will act as sales agent for any sales made under this new ATM program. The shares of common stock will be sold at market prices prevailing at the time of the sale of such shares and, as a result, sale prices may vary. EYEG: 1.56 (-0.05)
Eyegate Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update
GlobeNewswire - Fri May 13, 4:24PM CDT
Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company"
, a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced financial results for the three-month period ended March 31, 2016 and provided an update on recent corporate and operational initiatives. EYEG: 1.56 (-0.05)
EyeGate Pharma Appoints Dr. Brenda K. Mann as Vice President, Research and Development
GlobeNewswire - Fri May 06, 7:30AM CDT
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company"
, a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that, following the Company's recent acquisition of Jade Therapeutics, former Jade Vice President of Research and Development, Dr. Brenda K. Mann, was named Vice President, Research and Development at EyeGate. Dr. Mann is responsible for overseeing the Company's scientific development strategy, managing portfolio assets including early stage programs and building the company's scientific direction. EYEG: 1.56 (-0.05)
EyeGate Pharma Appoints Ryan R. Brenneman as Chief Financial Officer
GlobeNewswire - Wed Apr 27, 3:05PM CDT
EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company"
, a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced the appointment of Ryan R. Brenneman, CPA, JD, as its Chief Financial Officer, effective April 25, 2016. Mr. Brenneman will lead the Company's financial and administrative operations. EYEG: 1.56 (-0.05)
EyeGate Pharma to Present Four Posters at ARVO 2016 Annual Meeting Supporting Development of CMHA-S
GlobeNewswire - Tue Apr 26, 7:30AM CDT
Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company"
, a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that four abstracts supporting the ongoing development of its proprietary technology cross-linked hyaluronic acid polymer (CMHA-S) have been accepted for poster presentation at the upcoming 2016 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) being held May 1-5, 2016 in Seattle, WA. EYEG: 1.56 (-0.05)
4 Stocks That are Making Big Moves Early Today
ACCESSWIRE - Tue Feb 02, 9:23AM CST
NEW YORK, NY / ACCESSWIRE / February 2, 2016 / The Stock Expert is issuing a report on four stocks to watch. HDP, EYEG, LOJN and HNSN have been attracting the attention of major investors today. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
HDP: 8.78 (+0.51), HNSN: 3.99 (unch), LOJN: 6.44 (-0.01), EYEG: 1.56 (-0.05)
Macular Edema - Pipeline Review 2015
M2 - Fri Jan 29, 9:58AM CST
Research and Markets (http://www.researchandmarkets.com/research/3t295k/macular_edema) has announced the addition of the "Macular Edema - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Macular Edema and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - ActiveSite Pharmaceuticals, Inc. - Allergan Plc - Chong Kun Dang Pharmaceutical Corp. - Clearside BioMedical, Inc. - EyeGate Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - Mabion SA - Pfizer Inc. - Promedior, Inc. - Taiwan Liposome Company, Ltd. - Xbrane Bioscience AB Key Topics Covered: - Introduction - Macular Edema Overview - Therapeutics Development - Pipeline Products for Macular Edema - Overview - Pipeline Products for Macular Edema - Comparative Analysis - Macular Edema - Therapeutics under Development by Companies - Macular Edema - Therapeutics under Investigation by Universities/Institutes - Macular Edema - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Macular Edema - Products under Development by Companies - Macular Edema - Products under Investigation by Universities/Institutes - Macular Edema - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/3t...ular_edema
AGN: 243.43 (+5.02), CLSD: 11.75 (-0.13), EYEG: 1.56 (-0.05), PFE: 34.15 (-0.13)
Cataract - Pipeline Review - Companies Mentioned Include EyeGate Pharmaceuticals, InSite Vision Incorporated, Laboratories Sophia S.A. de C.V., Omeros Corporation & R-Tech Ueno
M2 - Fri Jan 29, 4:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/bvgpjg/cataract) has announced the addition of the "Cataract - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cataracts, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cataract and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - EyeGate Pharmaceuticals, Inc. - InSite Vision Incorporated - Laboratorios Sophia S.A. de C.V. - Omeros Corporation - R-Tech Ueno, Ltd. Key Topics Covered: - Introduction - Cataract Overview - Therapeutics Development - Pipeline Products for Cataract - Overview - Pipeline Products for Cataract - Comparative Analysis - Cataract- Therapeutics under Development by Companies - Cataract- Therapeutics under Investigation by Universities/Institutes - Cataract- Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Cataract- Products under Development by Companies - Cataract- Products under Investigation by Universities/Institutes - Cataract- Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/bvgpjg/cataract
EYEG: 1.56 (-0.05), OMER: 11.90 (+0.39)
Retinal Vein Occlusion Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/prcfm8/retinal_vein) has announced the addition of the "Retinal Vein Occlusion - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinal Vein Occlusion, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinal Vein Occlusion and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Retinal Vein Occlusion Overview - Therapeutics Development - Pipeline Products for Retinal Vein Occlusion - Overview - Pipeline Products for Retinal Vein Occlusion - Comparative Analysis - Retinal Vein Occlusion - Therapeutics under Development by Companies - Retinal Vein Occlusion - Therapeutics under Investigation by Universities/Institutes - Retinal Vein Occlusion - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Retinal Vein Occlusion - Products under Development by Companies - Retinal Vein Occlusion - Products under Investigation by Universities/Institutes - Retinal Vein Occlusion - Companies Involved in Therapeutics Development - Aerpio Therapeutics, Inc. - Allergan Plc - Avalanche Biotechnologies, Inc. - EyeGate Pharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Kala Pharmaceuticals, Inc. - Mabion SA - NicOx S.A. - Ohr Pharmaceutical Inc. - pSivida Corp. - ThromboGenics NV For more information visit http://www.researchandmarkets.com/research/pr...tinal_vein
AGN: 243.43 (+5.02), EYEG: 1.56 (-0.05), OHRP: 2.78 (+0.03), AAVL: 4.14 (-0.18)
EyeGate Pharma Enrolls First Patient in Confirmatory Phase 3 Clinical Trial EGP-437-006 for Non-Infectious Anterior Uveitis
GlobeNewswire - Tue Jan 19, 7:30AM CST
Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company"
, a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that the first patient was enrolled in the Company's confirmatory Phase 3 clinical trial of its EGP-437 combination product, the Company's lead product, in patients with non-infectious anterior uveitis, an inflammation of the anterior chamber of the eye. EYEG: 1.56 (-0.05)
Eyegate Pharmaceuticals to Present at the Noble Financial Capital Markets' 12th Annual Investor Conference
GlobeNewswire - Thu Jan 14, 8:49AM CST
Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (NASDAQ:EYEGW) ("EyeGate" or the "Company"
, a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced Stephen From, President & Chief Executive Officer of EyeGate, is scheduled to present at the Noble Financial Capital Markets' 12 Annual Conference, being held January 17-20, 2016 in Sandpiper Bay, Florida. EYEG: 1.56 (-0.05), EYEGW: 0.50 (-0.17)
Diabetic Macular Edema Pipeline Review, H2 2015
M2 - Fri Dec 04, 5:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/nznc34/diabetic_macular) has announced the addition of the "Diabetic Macular Edema - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Macular Edema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Aciont Inc. - ActiveSite Pharmaceuticals, Inc. - Acucela Inc. - Aerpio Therapeutics, Inc. - Allergan Plc - Ampio Pharmaceuticals, Inc. - Astellas Pharma Inc. - Avalanche Biotechnologies, Inc. - Chengdu Kanghong Pharmaceuticals Group Co., Ltd. - Chong Kun Dang Pharmaceutical Corp. - Dyax Corp. - EyeGate Pharmaceuticals, Inc. - EyeGene, Inc. - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Genmab A/S - Icon Bioscience, Inc. - Kala Pharmaceuticals, Inc. - Kowa Company, Ltd. - Mabion SA - MacuCLEAR, Inc. - NicOx S.A. - Oculis ehf - Ohr Pharmaceutical Inc. - Pfizer Inc. - Quark Pharmaceuticals, Inc. - R-Tech Ueno, Ltd. - Regeneron Pharmaceuticals, Inc. - Santen Pharmaceutical Co., Ltd. - SciFluor Life Sciences, LLC - Senju Pharmaceutical Co., Ltd. - ThromboGenics NV - Verseon Corporation For more information visit http://www.researchandmarkets.com/research/nz...ic_macular
PFE: 34.15 (-0.13), AMPE: 0.89 (unch), DYAX: 38.04 (-0.37), AGN: 243.43 (+5.02), EYEG: 1.56 (-0.05), AAVL: 4.14 (-0.18), OHRP: 2.78 (+0.03), REGN: 408.01 (+1.49)
EyeGate Reports Third Quarter 2015 Financial Results and Provides Business Update
GlobeNewswire - Thu Nov 12, 7:30AM CST
Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) ("EyeGate" or the "Company"
, a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced financial results for the three months ended September 30, 2015 and provided an update on recent strategic and operational initiatives. VRX: 26.85 (-0.12), EYEG: 1.56 (-0.05), VRX.TO: 35.07 (-0.27)
